AIM vs. RANI, ALXO, TPST, TENX, DARE, CLDI, GDTC, SLGL, PULM, and BCAB
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Rani Therapeutics (RANI), ALX Oncology (ALXO), Tempest Therapeutics (TPST), Tenax Therapeutics (TENX), Dare Bioscience (DARE), Calidi Biotherapeutics (CLDI), CytoMed Therapeutics (GDTC), Sol-Gel Technologies (SLGL), Pulmatrix (PULM), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry.
AIM ImmunoTech vs. Its Competitors
Rani Therapeutics (NASDAQ:RANI) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.
Rani Therapeutics has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. AIM ImmunoTech's return on equity of -421.73% beat Rani Therapeutics' return on equity.
Rani Therapeutics has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
AIM ImmunoTech has lower revenue, but higher earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 45.1% of Rani Therapeutics shares are held by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Rani Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 1,589.71%. AIM ImmunoTech has a consensus price target of $275.00, suggesting a potential upside of 3,017.91%. Given AIM ImmunoTech's higher possible upside, analysts clearly believe AIM ImmunoTech is more favorable than Rani Therapeutics.
In the previous week, Rani Therapeutics had 2 more articles in the media than AIM ImmunoTech. MarketBeat recorded 2 mentions for Rani Therapeutics and 0 mentions for AIM ImmunoTech. AIM ImmunoTech's average media sentiment score of 0.68 beat Rani Therapeutics' score of 0.18 indicating that AIM ImmunoTech is being referred to more favorably in the news media.
Summary
Rani Therapeutics beats AIM ImmunoTech on 9 of the 15 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
This page (NYSE:AIM) was last updated on 7/22/2025 by MarketBeat.com Staff
Free AIM Stock Alerts